(Q37138213)

18 August 2017

Antibody-drug conjugates: Intellectual property considerations (English)

1 reference

18 August 2017

intellectual property

0 references

author name string

Ulrich Storz

series ordinal

1

1 reference

18 August 2017

20 August 2015

1 reference

18 August 2017

Monoclonal Antibodies

1 reference

18 August 2017

7

1 reference

18 August 2017

6

1 reference

18 August 2017

989-1009

1 reference

Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Rituximab: how approval history is reflected by a corresponding patent filing strategy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Antibody-drug conjugate target selection: critical factors

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Antibody conjugate therapeutics: challenges and potential

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

The market for follow-on biologics: how will it evolve?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Immunoconjugates containing novel maytansinoids: promising anticancer drugs

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

Antibody-drug conjugates: present and future.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966491

In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26292154

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/19420862.2015.1082019

1 reference

18 August 2017

1 reference

PMC publication ID

4966491

18 August 2017

PubMed publication ID

26292154

1 reference

PMC publication ID

4966491